Navigation Links
Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
Date:7/17/2008

- PFS data from Neuradiab(TM) compares favorably to data from other

technologies -

TSX: BMR

TORONTO, July 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today released progression free survival (PFS) data from two previously conducted Phase II trials of Neuradiab(TM) in glioblastoma multiforme (GBM) patients. As an exploratory endpoint of the single arm Phase II trials, the data showed a mean overall PFS of 17.2 months in 19 GBM patients treated with Neuradiab. Bradmer is currently conducting a Phase III clinical trial, termed the GLASS-ART Trial, evaluating Neuradiab as an adjunct therapy to the current standard of care for GBM patients. The primary endpoint of the GLASS-ART Trial is the increase in median overall survival in the treated arm compared to the standard of care control arm.

"These PFS data from the Phase II Neuradiab trials exceed the results achieved in any other clinical trial in newly-diagnosed GBM to our knowledge. This is compelling because of recent inquiries from the U.S. Food and Drug Administration (FDA) which suggested that Bradmer may opt to evaluate sensitivities around the merits and use of PFS as an additional interim marker of prognostic benefit," said Dr. Alan M. Ezrin, President and Chief Executive Officer of Bradmer. "While the GLASS-ART Trial is being conducted with a clear primary endpoint of median overall survival, the opportunity for Neuradiab to demonstrate a patient benefit via the parameter of PFS could provide an augmented regulatory approval path. We have examined the PFS outcomes from the previous studies of Neuradiab and intend to discuss with the FDA the most appropriate method in which to use PFS data from the GLASS-ART Trial."

Recent communications from the FDA have led Bradmer to consider using PFS data not only as a secondary endpoint in the GLASS-ART Trial
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Reports Progress on Its AIDS Vaccine Technology
2. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
3. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
4. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
5. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
6. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
7. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
8. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
9. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
10. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
11. Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:1/15/2014)... N.Y. , Jan. 15, 2014 Sono-Tek Corporation (OTC ... months ended November 30, 2013, compared to sales of $2,202,000 ... 20%. Once again, this quarter has also shown growth over ... the first quarter of this fiscal year. Markets that experienced ...
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, ... company developing medical countermeasures against biological and chemical threats, ... call for investors on Wednesday, April 29th beginning at ... rPA anthrax vaccine program. The dial-in number within the ...
... Urological Association Annual Meeting --SEATTLE and CHICAGO, April ... DNDN ) today presented preclinical data demonstrating ... molecule, which targets TRPM8 (a transmembrane cation channel ... D-3263 demonstrated the ability to reduce BPH alone ...
Cached Medicine Technology:PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program 2Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 4
(Date:7/12/2014)... 2014 In this cognitive ... assessment and training’ is defined as solution ... or enhance cognitive functions. These solutions are ... dementia screening, clinical trials, driver’s safety, rehabilitation, ... assessment, brain training, and employers’ assessment and ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The Security ... in 2013 to $3,376.6 million by 2019, at an ... and 2019. The challenges to counter the increasing number ... existence of outdated cyber defense systems in organizations are ... innovating and remodeling their existing architecture to develop better ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... damage allegations continue to move forward in the ... Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... U.S. District Judge Lawrence F. Stengel has ordered ... other things, Judge Stengel found that the witness’s ...
(Date:7/12/2014)... (HealthDay News) -- If you make exercise fun, you,ll eat ... experiment, 56 adults were led on a 1.4-mile walk and ... a scenic walk. The participants were given lunch after the ... outing ate 35 percent more chocolate pudding for dessert than ... In another experiment, 46 adults were given mid-afternoon snacks after ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 "The second toes ... uncomfortable and painful to wear shoes," said an inventor from ... sock that prevents this from happening. , He then created ... way to prevent the second and big toes from overlapping. ... while wearing shoes. Ergonomic and easy to use, it's ideal ...
Breaking Medicine News(10 mins):Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Make Exercise Fun, Eat Less Afterwards 2
... you think. Low doses of radiation have been found to ... not uncommon for children who suffer from medulloblastoma to undergo ... in affecting IQ and reading skills of younger children rather ... has been found that the greatest rates of decline in ...
... has claimed at least 20 lives in the past two ... is already present in the neighboring Indian state of UP ... caused 10 deaths each in the townships of Tikapur and ... over 80 patients were undergoing treatment in various hospitals and ...
... that the loss of a gene called p63 accelerates the ... present in many organisms, including humans // . Drawing parallels ... is likely to play a fundamental biological role in aging-related ... researchers had devised a system for eliminating it from adult ...
... prevent infections in older people living at home, report ... segment of the supplement-taking population. //, ,Studies in ... supplements, elderly people in nursing homes were 20 per ... had fewer colds over the study period than a ...
... at Jefferson Medical College had discovered the existence of ... biomarker for conditions that lead to heart failures. Based ... a blood test to predict the onset of heart ... previously showed that an enzyme called GRK2 or beta-adrenergic ...
... become nearly twice as prevalent in high schools in the ... middle school students admit that drugs are used, kept or ... where drugs are widely available are three times more likely ... alcohol than their peers who attend drug-free schools., ,Availability ...
Cached Medicine News:Health News:Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly 2Health News:Blood Test To Predict Heart Failures 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: